Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (LGND)
NASDAQ:LGND
Holding LGND?
Track your performance easily
Earnings Data
Report Date
Feb 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$1.18Last Year’s EPS
$1.38Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -1.93%
|Next Earnings Date:Feb 06, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong quarter for Ligand with significant revenue growth and successful product launches. Financial guidance was raised, indicating confidence in continued momentum. However, there were some challenges, including a decline in Captisol sales and increased operating expenses. Overall, the positives in revenue growth, product launches, and strong financial outlook significantly outweighed the negatives.Company Guidance
During Ligand's Q3 2024 earnings call, the company delivered impressive financial results, with total revenues reaching $51.8 million, marking a 58% year-over-year increase. This strong performance led to an upward revision in guidance for the year, projecting total revenues between $100 million and $165 million and adjusted EPS between $5.50 and $5.70, a 38% increase from 2023. Key financial drivers included a 33% rise in royalty revenue to $31.7 million, bolstered by strong sales of Amgen's Kyropolis and Travere's FILSPARI, the latter contributing to a 9% royalty on global net sales. Additionally, new commercial products like QARZIBA, CAPVAXIVE, and Ohtuvayre are expected to significantly impact future royalties, contributing to a projected royalty revenue CAGR exceeding 22%. The company is well-capitalized with access to over $300 million, supporting its strategy to acquire high-value royalty-generating assets.Record Revenue Growth
Total revenue grew by 58% over the prior year, with royalty revenue increasing by 33%.
Increased Financial Guidance
Guidance was increased for the second time this year, with 2024 total revenue now expected to be between $100 million to $165 million and adjusted EPS between $5.50 and $5.70.
Strong Launches of Key Products
Successful launches of Verona Pharma's Ohtuvayre and Merck's CAPVAXIVE, both expected to be significant contributors to royalty revenue.
FDA Approvals and Expansion
FDA granted full approval for FILSPARI, expanding its indication, and there is potential for further indication expansion in FSGS.
Robust Investment Pipeline
Over 20 investment opportunities are being reviewed, representing more than $800 million of investment potential.
Strong Balance Sheet
The company has access to over $300 million in capital and ended the quarter with $350 million in available investable capital.
---
LGND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LGND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $116.90 | $129.90 | +11.12% |
| Aug 06, 2024 | $99.04 | $93.32 | -5.78% |
| May 07, 2024 | $73.22 | $80.36 | +9.75% |
| Feb 27, 2024 | $74.42 | $89.20 | +19.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ligand Pharma (LGND) report earnings?
Ligand Pharma (LGND) is schdueled to report earning on Feb 06, 2025, TBA Not Confirmed.
What is Ligand Pharma (LGND) earnings time?
Ligand Pharma (LGND) earnings time is at Feb 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LGND EPS forecast?
LGND EPS forecast for the fiscal quarter 2024 (Q4) is $1.18.
---